Loading…

Stem cell therapy for heart diseases

Cardiovascular disease is the leading cause of morbidity and mortality worldwide. Despite the advances in medical and catheter-based therapy for acute myocardial infarction the 1-year mortality remains as high as 13% and the 5-year prognosis for patients with heart failure remains as high as 50%. Le...

Full description

Saved in:
Bibliographic Details
Published in:British medical bulletin 2011-06, Vol.98 (1), p.143-159
Main Authors: MOZID, Abdul M, ARNOUS, Samer, SAMMUT, Eva C, MATHUR, Anthony
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c316t-3dafcbe7101c0bcab125fb695e3924b8b0b1672590201d6231944871245985273
cites cdi_FETCH-LOGICAL-c316t-3dafcbe7101c0bcab125fb695e3924b8b0b1672590201d6231944871245985273
container_end_page 159
container_issue 1
container_start_page 143
container_title British medical bulletin
container_volume 98
creator MOZID, Abdul M
ARNOUS, Samer
SAMMUT, Eva C
MATHUR, Anthony
description Cardiovascular disease is the leading cause of morbidity and mortality worldwide. Despite the advances in medical and catheter-based therapy for acute myocardial infarction the 1-year mortality remains as high as 13% and the 5-year prognosis for patients with heart failure remains as high as 50%. Left ventricular systolic dysfunction, a major determinant of prognosis, is associated with significant loss of cardiomyocytes which was previously thought to be irreversible as the heart was considered a post-mitotic organ. Review of literature published in peer reviewed journals and ClinicalTrials.Gov website. There is now growing evidence that the human heart is capable of undergoing repair and in recent years there has been an increase in basic and clinical research with the aim of harnessing the regenerative properties of stem cells in order to facilitate restoration of myocardial function. The mechanisms of action of cell therapy with regards to cardiac repair remain unsatisfactorily understood and the magnitude of benefit demonstrated in animal models is yet to be fully translated in humans. The number of clinical trials continues to increase and include treating patients with acute myocardial infarction and chronic heart failure secondary to ischaemic heart disease or dilated cardiomyopathy. The future of this field of research will require closer collaboration between scientists and clinicians to understand how cell therapy works and to define the ideal cell type and method of delivery to be able to derive maximum benefit.
doi_str_mv 10.1093/bmb/ldr014
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_871378504</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>871378504</sourcerecordid><originalsourceid>FETCH-LOGICAL-c316t-3dafcbe7101c0bcab125fb695e3924b8b0b1672590201d6231944871245985273</originalsourceid><addsrcrecordid>eNpF0EtLw0AUhuFBFFurG3-AZKEIQuw5c8lkllK8QcGFuh5mJhMaSZo4ky76701J1NXZPHwcXkIuEe4RFFvaxi7rIgDyIzJHLjHNmcJjMgcAmSKnMCNnMX4BIGOQn5IZRaEyiWxOrt973yTO13XSb3ww3T4p25BsvAl9UlTRm-jjOTkpTR39xXQX5PPp8WP1kq7fnl9XD-vUMcz6lBWmdNZLBHRgnbFIRWkzJTxTlNvcgsVMUqGAAhYZZag4zyVSLlQuqGQLcjvudqH93vnY66aKh9_M1re7qAfLZC6AD_JulC60MQZf6i5UjQl7jaAPUfQQRY9RBnw1ze5s44s_-lthADcTMNGZugxm66r47ziVHKhgP0-DZ50</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>871378504</pqid></control><display><type>article</type><title>Stem cell therapy for heart diseases</title><source>Oxford Journals Online</source><creator>MOZID, Abdul M ; ARNOUS, Samer ; SAMMUT, Eva C ; MATHUR, Anthony</creator><creatorcontrib>MOZID, Abdul M ; ARNOUS, Samer ; SAMMUT, Eva C ; MATHUR, Anthony</creatorcontrib><description>Cardiovascular disease is the leading cause of morbidity and mortality worldwide. Despite the advances in medical and catheter-based therapy for acute myocardial infarction the 1-year mortality remains as high as 13% and the 5-year prognosis for patients with heart failure remains as high as 50%. Left ventricular systolic dysfunction, a major determinant of prognosis, is associated with significant loss of cardiomyocytes which was previously thought to be irreversible as the heart was considered a post-mitotic organ. Review of literature published in peer reviewed journals and ClinicalTrials.Gov website. There is now growing evidence that the human heart is capable of undergoing repair and in recent years there has been an increase in basic and clinical research with the aim of harnessing the regenerative properties of stem cells in order to facilitate restoration of myocardial function. The mechanisms of action of cell therapy with regards to cardiac repair remain unsatisfactorily understood and the magnitude of benefit demonstrated in animal models is yet to be fully translated in humans. The number of clinical trials continues to increase and include treating patients with acute myocardial infarction and chronic heart failure secondary to ischaemic heart disease or dilated cardiomyopathy. The future of this field of research will require closer collaboration between scientists and clinicians to understand how cell therapy works and to define the ideal cell type and method of delivery to be able to derive maximum benefit.</description><identifier>ISSN: 0007-1420</identifier><identifier>EISSN: 1471-8391</identifier><identifier>DOI: 10.1093/bmb/ldr014</identifier><identifier>PMID: 21596713</identifier><identifier>CODEN: BMBUAQ</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Applied cell therapy and gene therapy ; Biological and medical sciences ; Cardiomyopathy, Dilated - therapy ; Clinical Trials as Topic ; General aspects ; Heart Diseases - therapy ; Heart Failure - therapy ; Humans ; Medical sciences ; Myocardial Infarction - therapy ; Stem Cell Transplantation - methods ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><ispartof>British medical bulletin, 2011-06, Vol.98 (1), p.143-159</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c316t-3dafcbe7101c0bcab125fb695e3924b8b0b1672590201d6231944871245985273</citedby><cites>FETCH-LOGICAL-c316t-3dafcbe7101c0bcab125fb695e3924b8b0b1672590201d6231944871245985273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=24274025$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21596713$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MOZID, Abdul M</creatorcontrib><creatorcontrib>ARNOUS, Samer</creatorcontrib><creatorcontrib>SAMMUT, Eva C</creatorcontrib><creatorcontrib>MATHUR, Anthony</creatorcontrib><title>Stem cell therapy for heart diseases</title><title>British medical bulletin</title><addtitle>Br Med Bull</addtitle><description>Cardiovascular disease is the leading cause of morbidity and mortality worldwide. Despite the advances in medical and catheter-based therapy for acute myocardial infarction the 1-year mortality remains as high as 13% and the 5-year prognosis for patients with heart failure remains as high as 50%. Left ventricular systolic dysfunction, a major determinant of prognosis, is associated with significant loss of cardiomyocytes which was previously thought to be irreversible as the heart was considered a post-mitotic organ. Review of literature published in peer reviewed journals and ClinicalTrials.Gov website. There is now growing evidence that the human heart is capable of undergoing repair and in recent years there has been an increase in basic and clinical research with the aim of harnessing the regenerative properties of stem cells in order to facilitate restoration of myocardial function. The mechanisms of action of cell therapy with regards to cardiac repair remain unsatisfactorily understood and the magnitude of benefit demonstrated in animal models is yet to be fully translated in humans. The number of clinical trials continues to increase and include treating patients with acute myocardial infarction and chronic heart failure secondary to ischaemic heart disease or dilated cardiomyopathy. The future of this field of research will require closer collaboration between scientists and clinicians to understand how cell therapy works and to define the ideal cell type and method of delivery to be able to derive maximum benefit.</description><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Applied cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Cardiomyopathy, Dilated - therapy</subject><subject>Clinical Trials as Topic</subject><subject>General aspects</subject><subject>Heart Diseases - therapy</subject><subject>Heart Failure - therapy</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Myocardial Infarction - therapy</subject><subject>Stem Cell Transplantation - methods</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><issn>0007-1420</issn><issn>1471-8391</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNpF0EtLw0AUhuFBFFurG3-AZKEIQuw5c8lkllK8QcGFuh5mJhMaSZo4ky76701J1NXZPHwcXkIuEe4RFFvaxi7rIgDyIzJHLjHNmcJjMgcAmSKnMCNnMX4BIGOQn5IZRaEyiWxOrt973yTO13XSb3ww3T4p25BsvAl9UlTRm-jjOTkpTR39xXQX5PPp8WP1kq7fnl9XD-vUMcz6lBWmdNZLBHRgnbFIRWkzJTxTlNvcgsVMUqGAAhYZZag4zyVSLlQuqGQLcjvudqH93vnY66aKh9_M1re7qAfLZC6AD_JulC60MQZf6i5UjQl7jaAPUfQQRY9RBnw1ze5s44s_-lthADcTMNGZugxm66r47ziVHKhgP0-DZ50</recordid><startdate>20110601</startdate><enddate>20110601</enddate><creator>MOZID, Abdul M</creator><creator>ARNOUS, Samer</creator><creator>SAMMUT, Eva C</creator><creator>MATHUR, Anthony</creator><general>Oxford University Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110601</creationdate><title>Stem cell therapy for heart diseases</title><author>MOZID, Abdul M ; ARNOUS, Samer ; SAMMUT, Eva C ; MATHUR, Anthony</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c316t-3dafcbe7101c0bcab125fb695e3924b8b0b1672590201d6231944871245985273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Applied cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Cardiomyopathy, Dilated - therapy</topic><topic>Clinical Trials as Topic</topic><topic>General aspects</topic><topic>Heart Diseases - therapy</topic><topic>Heart Failure - therapy</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Myocardial Infarction - therapy</topic><topic>Stem Cell Transplantation - methods</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MOZID, Abdul M</creatorcontrib><creatorcontrib>ARNOUS, Samer</creatorcontrib><creatorcontrib>SAMMUT, Eva C</creatorcontrib><creatorcontrib>MATHUR, Anthony</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>British medical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MOZID, Abdul M</au><au>ARNOUS, Samer</au><au>SAMMUT, Eva C</au><au>MATHUR, Anthony</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stem cell therapy for heart diseases</atitle><jtitle>British medical bulletin</jtitle><addtitle>Br Med Bull</addtitle><date>2011-06-01</date><risdate>2011</risdate><volume>98</volume><issue>1</issue><spage>143</spage><epage>159</epage><pages>143-159</pages><issn>0007-1420</issn><eissn>1471-8391</eissn><coden>BMBUAQ</coden><abstract>Cardiovascular disease is the leading cause of morbidity and mortality worldwide. Despite the advances in medical and catheter-based therapy for acute myocardial infarction the 1-year mortality remains as high as 13% and the 5-year prognosis for patients with heart failure remains as high as 50%. Left ventricular systolic dysfunction, a major determinant of prognosis, is associated with significant loss of cardiomyocytes which was previously thought to be irreversible as the heart was considered a post-mitotic organ. Review of literature published in peer reviewed journals and ClinicalTrials.Gov website. There is now growing evidence that the human heart is capable of undergoing repair and in recent years there has been an increase in basic and clinical research with the aim of harnessing the regenerative properties of stem cells in order to facilitate restoration of myocardial function. The mechanisms of action of cell therapy with regards to cardiac repair remain unsatisfactorily understood and the magnitude of benefit demonstrated in animal models is yet to be fully translated in humans. The number of clinical trials continues to increase and include treating patients with acute myocardial infarction and chronic heart failure secondary to ischaemic heart disease or dilated cardiomyopathy. The future of this field of research will require closer collaboration between scientists and clinicians to understand how cell therapy works and to define the ideal cell type and method of delivery to be able to derive maximum benefit.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>21596713</pmid><doi>10.1093/bmb/ldr014</doi><tpages>17</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0007-1420
ispartof British medical bulletin, 2011-06, Vol.98 (1), p.143-159
issn 0007-1420
1471-8391
language eng
recordid cdi_proquest_miscellaneous_871378504
source Oxford Journals Online
subjects Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Applied cell therapy and gene therapy
Biological and medical sciences
Cardiomyopathy, Dilated - therapy
Clinical Trials as Topic
General aspects
Heart Diseases - therapy
Heart Failure - therapy
Humans
Medical sciences
Myocardial Infarction - therapy
Stem Cell Transplantation - methods
Transfusions. Complications. Transfusion reactions. Cell and gene therapy
title Stem cell therapy for heart diseases
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T17%3A59%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stem%20cell%20therapy%20for%20heart%20diseases&rft.jtitle=British%20medical%20bulletin&rft.au=MOZID,%20Abdul%20M&rft.date=2011-06-01&rft.volume=98&rft.issue=1&rft.spage=143&rft.epage=159&rft.pages=143-159&rft.issn=0007-1420&rft.eissn=1471-8391&rft.coden=BMBUAQ&rft_id=info:doi/10.1093/bmb/ldr014&rft_dat=%3Cproquest_cross%3E871378504%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c316t-3dafcbe7101c0bcab125fb695e3924b8b0b1672590201d6231944871245985273%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=871378504&rft_id=info:pmid/21596713&rfr_iscdi=true